In a nutshell This study aims to compare ixazomib plus dexamethasone versus pomalidomide plus dexamethasone on survival in participants with relapse and/or refractory multiple myeloma. The outcome to be measured is the duration of time until disease progresses (worsens). The details Multiple myeloma is a cancer of the plasma cells in the...
Read More
In a nutshell This study aims to compare bortezomib, lenalidomide, and dexamethasone with carfilzomib, lenalidomide, and dexamethasone. The outcome to be measured is the overall survival (time from treatment until death from any cause). The details Multiple myeloma is a cancer of the plasma cells in the blood. Treatment for multiple myeloma...
Read More
In a nutshell This trial is examining the effectiveness of the antibody-drug conjugate SYD985 for HER2-positive inoperable advanced breast cancer. The main outcome to be measured will be time from treatment until disease progression or the time taken for tumor growth or spread. This study is being conducted in Baltimore, Maryland, inthe United...
Read More
In a nutshell This phase 2 trial aims to test the effectiveness of a combined treatment with Brentuximab vedotin (Adcetris) in patients 60 years of age or more with Hodgkin lymphoma. The main outcome to be measured will be tumor response to the treatment and side effects. This trial is recruiting throughout the United States. The details...
Read More
In a nutshell This study aimed to compare abemaciclib (Verzenio) to a placebo treatment (substance with no active effect). The study concluded that it increased progression-free survival and was relatively safe to use as a first-line treatment. Some background There are several treatment options for hormone positive, HER-2 negative...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of merestinib in non-small cell lung cancer patients with a mutation in the MET protein. The primary outcome will be measured by the overall response to the treatment. This study is being conducted in Boston, Massachusetts. The details Merestinib is an inhibitor of the C-Met...
Read More
In a nutshell This phase 2 trial will clinical trial will test the effectiveness of lorlatinib in treating non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) mutations. The primary outcome will be measured by the rate at which the disease spreads to the central nervous system (CNS). The...
Read More
In a nutshell This multicenter phase 3 clinical trial will test the effectiveness of nivolumab (Opdivo) after surgery and chemotherapy in stage 1b to 3a non-small cell lung cancer (NSCLC). The primary outcome will be measured by the length of time the patient survives without signs of the cancer and the overall survival rate for up to 10...
Read More
In a nutshell This phase 1 clinical trial will test the safety of blinatumomab (Blincyto) treatment after high-dose melphalan (Alkeran) and autologous stem cell transplant in patients with refractory (unresponsive to treatment) multiple myeloma. The primary outcome will be measured by the number of adverse (negative) effects. The trial is being...
Read More
In a nutshell This phase 3 clinical trial will test the effectiveness of ibrutinib (Imbruvica) during and after stem cell transplant in patients with relapsed or refractory diffuse large B-cell lymphoma. The primary outcome will be measured by the time to disease progression. The details Ibrutinib is a drug that stops the growth of...
Read More
In a nutshell This phase 1/2 clinical trial will test the response to AFM13 in patients with relapsed or refractory cutaneous (on the skin) CD30 positive lymphomas. The primary outcome will be measured by immune system activity. This study will be conducted at the Center for Lymphoid Malignancies in New York, New York. The details AFM13 is an...
Read More
In a nutshell This phase 2 clinical trial will test the safety and tolerability of a nivolumab (Opdivo) and 5-azacytidine (Vidaza) combination with or without ipilimumab (Yervoy) in treating relapsed or refractory (unresponsive to treatment) acute myeloid leukemia (AML). The primary outcome will be measured by the maximum tolerated dose. This trial is...
Read More
